Table 2. Laboratory findings and medications in COVID-19 subjects*.
| Laboratory Values | All (n = 60 patients) | COVID-19 Retinopathy (n = 12 patients) | No COVID-19 Retinopathy (n = 48 patients) | Odds Ratio | p-value |
|---|---|---|---|---|---|
| D-dimer, Peak, mg/mL | 1583 (906, 7032) | 5703 (1018, 13746) | 1548.5 (889, 5595) | 1.03 (0.96, 1.10)1 | 0.48 |
| Fibrinogen, Nadir, mg/dL | 363 (211, 488) (n = 25) | 488 (175, 589) | 353 (266, 488) | 1.07 (0.66, 1.74)2 | 0.83 |
| C-reactive protein, mg/L | 111.4 (57.1, 162.9) (n = 57) | 121.7 (80.1, 165.1) | 97.6 (53.7, 162.9) | 1.04 (0.74, 1.46)3 | 0.81 |
| Interleukin-6, pg/mL | 5.8 (2.3, 9.2) (n = 9) | 2 (2, 25) | 6.5 (3.7, 9.2) | n/a | 0.75 |
| Platelets, Peak, x109 cells/L | 348 (292, 457.5) | 410.5 (365.5, 499.5) | 336 (280, 438.5) | 1.72 (0.99, 2.99)2 | 0.10 |
| Platelets, Nadir, x109 cells/L | 211 (150.5, 248.5) | 218 (151.5, 259) | 210 (150.5, 244.5) | 1.19 (0.51, 2.81)2 | 0.73 |
| Hematocrit, Nadir, % | 33.4 (27.6, 37.5) | 29.0 (25.7, 36.0) | 34.3 (28.8, 38.1) | 0.66 (0.39, 1.14)4 | 0.13 |
| WBC, Peak, x109 cells/L | 13.3 (7.4, 16.9) | 14.8 (11.8, 18.3) | 12 (7.15, 16.1) | 1.23 (0.82, 1.85)4 | 0.33 |
| WBC, Nadir, x109 cells/L | 6.1 (4.2, 8.0) | 5.9 (4.1, 8.4) | 6.2 (4.4, 8.0) | 0.84 (0.26, 2.74)4 | 0.78 |
| Lymphocytes, Peak, x109 cells/L | 16 (8, 30), (n = 51) | 16 (9, 30) | 16 (9, 30) | 1.02 (0.79, 1.33)4 | 0.87 |
| Lymphocytes, Nadir, x109 cells/L | 7 (3, 13), (n = 47) | 7 (3, 14) | 7 (3, 14) | 0.92 (0.60, 1.43)4 | 0.72 |
*Values represented as medians and interquartile ranges (Q1, Q3)
1Per 1000 unit increase
2Per 100 unit increase
3Per 50 unit increase
4Per 5 unit increase